Advertisement
Canada markets closed
  • S&P/TSX

    21,823.22
    +94.67 (+0.44%)
     
  • S&P 500

    5,064.20
    +45.81 (+0.91%)
     
  • DOW

    38,225.66
    +322.37 (+0.85%)
     
  • CAD/USD

    0.7319
    +0.0005 (+0.07%)
     
  • CRUDE OIL

    79.12
    +0.17 (+0.22%)
     
  • Bitcoin CAD

    81,948.95
    +3,523.43 (+4.49%)
     
  • CMC Crypto 200

    1,283.17
    +12.42 (+0.98%)
     
  • GOLD FUTURES

    2,310.60
    +1.00 (+0.04%)
     
  • RUSSELL 2000

    2,016.11
    +35.88 (+1.81%)
     
  • 10-Yr Bond

    4.5710
    -0.0240 (-0.52%)
     
  • NASDAQ futures

    17,762.75
    +113.00 (+0.64%)
     
  • VOLATILITY

    14.68
    -0.71 (-4.61%)
     
  • FTSE

    8,172.15
    +50.91 (+0.63%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • CAD/EUR

    0.6816
    -0.0001 (-0.01%)
     

Bausch Health to Announce First-Quarter 2024 Results on May 2

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Conference Call Details

Date:

Thursday, May 2, 2024

Time:

8:00 a.m. U.S. EDT

Webcast:

http://ir.bauschhealth.com/events-and-presentations

A replay of the conference call will be available on the investor relations website.

ADVERTISEMENT

To participate in the live Q&A session, please register using this link to receive a PIN, which will be sent an hour before the conference call.

About Bausch Health

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

###

Investor Contact:

Media Contact:

Garen Sarafian

Kevin Wiggins

ir@bauschhealth.com

corporate.communications@bauschhealth.com

(877) 281-6642 (toll-free)

(908) 541-3785

SOURCE: Bausch Health Companies Inc.



View the original press release on accesswire.com